Special Issue

Epigenetic Regulators and Cancer Precision Therapies

Message from the Guest Editor

Tumorigenesis originated from two gene alterations: a tumor suppressor gene and a proto-oncogene/oncogene. When this gene mutates, a tumor suppressor gene causes a loss or reduction in its protection. Epigenetics and epigenomics can improve our understanding of cancer development and progression, explain the regulation of gene expression, and address genomic function without the base-pair DNA sequence. This Special Issue, titled "**Epigenetic Regulators and Cancer Precision Therapies**", presents a collection of contributions by outstanding researchers that focus on the fields of cancer epigenetics and epigenomics for precision treatment. This collection of articles provides a snapshot of the latest research, encompassing diverse aspects of epigenetic regulation in cancer. We anticipate further breakthroughs that will transform the landscape of cancer treatment and improve patient outcomes.

Guest Editor

Dr. Biaoru Li
Department of Pediatrics, GA Cancer Center, Augusta, GA 30913, USA

Deadline for manuscript submissions

closed (31 October 2025)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/219933

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)